Geode Capital Management LLC boosted its position in shares of Cytosorbents Co. (NASDAQ:CTSO – Free Report) by 7.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 467,058 shares of the medical research company’s stock after buying an additional 32,415 shares during the quarter. Geode Capital Management LLC’s holdings in Cytosorbents were worth $701,000 at the end of the most recent quarter.
Separately, Sargent Investment Group LLC boosted its stake in Cytosorbents by 13.4% during the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after buying an additional 192,747 shares in the last quarter. Institutional investors own 32.87% of the company’s stock.
Cytosorbents Trading Down 3.3 %
NASDAQ:CTSO opened at $0.94 on Friday. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. Cytosorbents Co. has a 1-year low of $0.70 and a 1-year high of $1.59. The firm has a market capitalization of $51.27 million, a price-to-earnings ratio of -2.60 and a beta of 0.58. The stock has a fifty day simple moving average of $0.92 and a 200 day simple moving average of $1.03.
Analysts Set New Price Targets
Check Out Our Latest Research Report on CTSO
Cytosorbents Profile
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.
Featured Articles
- Five stocks we like better than Cytosorbents
- 10 Best Airline Stocks to Buy
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- Differences Between Momentum Investing and Long Term Investing
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- Conference Calls and Individual Investors
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Want to see what other hedge funds are holding CTSO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytosorbents Co. (NASDAQ:CTSO – Free Report).
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.